Skip to content
Wearables & measurementRandomised trial3 min read

Older cardiac rehab patients who wore a Fitbit consistently walked farther in 6 minutes

MoveVitals Editorial Collective · Study published · Reading updated

Original paper:Adherence to Accelerometer Use in Older Adults Undergoing mHealth Cardiac Rehabilitation: Secondary Analysis of a Randomized Clinical Trial. · Journal of medical Internet research · 2025 · Original paper ↗

Key takeaway

Among 271 older adults in a mobile cardiac rehabilitation program, the consistently high-wear cluster improved 6-minute walk distance by 38.5 meters (95% CI 2.2-74.7; P=.04) more than the low-adherence cluster in the 8-cluster analysis. The 2-cluster result was only a trend (24.6 meters, P=.06), so the evidence is weak and not causal.

Study design

Randomised trial

Reading basis

Published abstract

Reading focus

Comparator & uncertainty

The research question

Mobile health cardiac rehabilitation (mHealth-CR) often relies on wearable accelerometers, but it is not well understood whether wearing them consistently goes along with better recovery of functional capacity. The authors used an AI clustering method to find distinct patterns of device wear and tested how they relate to improvement in walking capacity.

Who and how

Secondary analysis of the RESILIENT randomized trial, which compared mHealth-CR with usual care in older adults (aged 65 or older) after hospitalization for ischemic heart disease. Intervention participants were told to wear a Fitbit for 3 months. Overall adherence (percentage of days worn) and wear patterns were characterized with k-means clustering at two resolutions (k=2 and k=8) and compared with change in 6-minute walk distance (6-MWD), adjusting for demographic and clinical covariates. Trial registration NCT03978130.

What it found

The authors’ reported results. Read each estimate with its population and uncertainty.

  1. 1
    Among 271 participants (mean age 71 years, SD 8; 198, 73%, male), the Fitbit was worn an average of 76 days over 3 months (95% confidence limits 73-78).
  2. 2
    Every 30 additional days of wear was weakly associated with an 11-meter improvement in 6-MWD (P=.08), which is not statistically significant.
  3. 3
    With 2 clusters, the consistently high adherence cluster trended toward a 24.6-meter improvement in 6-MWD versus the low and declining clusters (n=39; 95% CI 0.7-49.9; P=.06).
  4. 4
    With 8 clusters, the consistently high adherence cluster improved 38.5 meters more than the low adherence cluster (95% CI 2.2-74.7; P=.04) and walked more daily (mean 7518, SD 3415 versus mean 4800, SD 2920 steps; P=.008).

Limits & uncertainty

  1. 1
    The main wear-day association was not statistically significant (P=.08), and the cluster results sit close to the threshold with wide confidence intervals.
  2. 2
    The 8-cluster analysis was exploratory, and choosing the number of clusters after the fact can inflate apparent findings.
  3. 3
    People who wear devices more may also be healthier or more motivated, and daily steps differed between clusters, so wear and recovery may reflect those traits.
  4. 4
    Participants were mostly male older adults in one trial. This reading rests on the abstract only.

What to take from it

In this group, people who wore the tracker consistently tended to gain more walking distance, but the data cannot show that wearing it causes the gain. Wearing the device regularly is a sensible habit if your rehab team asks for it, but do not read the numbers as a promise. Cardiac rehabilitation plans are for your care team to set.

Reading your own data

If you are in a rehab program, wear your tracker consistently and keep the same device so daily steps are comparable. Look at the weekly trend and discuss it with your team, along with any walking test results.

How to read this evidence

Randomisation can support causal inference, but check allocation, blinding, missing outcomes, follow-up and the actual comparator. A trial label alone does not establish high certainty.

Authors’ structured abstract English

The attributed English abstract is reproduced under the recorded open licence. It is source material, not a MoveVitals interpretation. The prepared analysis above separates the authors’ findings from our interpretation.

Background

Wearable accelerometers, which continuously record physical activity metrics, are commonly used in mobile health-enabled cardiac rehabilitation (mHealth-CR). The association between adherence to accelerometer use during mHealth-CR and improvement in clinical outcomes, such as functional capacity, is understudied. The emergence of artificial intelligence (AI) technology provides novel opportunities to investigate accelerometry use patterns in relation to mHealth-CR outcomes.

Objective

In this study, we sought to use an AI clustering framework to identify distinct behavioral phenotypes of adherence to accelerometer use. We then aimed to quantify the association of these adherence phenotypes with functional capacity improvements in older adults undergoing mHealth-CR.

Methods

We analyzed data from the RESILIENT (Rehabilitation at Home Using Mobile Health in Older Adults After Hospitalization for Ischemic Heart Disease) trial, the largest randomized clinical study to date comparing mHealth-CR versus usual care in older adults (aged ≥65 years). Intervention arm participants were instructed to wear a Fitbit accelerometer for the 3-month study duration. Adherence to accelerometer use was quantified as overall adherence (percentage of days worn) via k-means clustering AI-derived measures and compared with changes in 6-minute walk distance (6-MWD), adjusted for demographic and clinical covariates.

Results

Among 271 participants with a mean age of 71 years (SD 8), of whom 198 (73%) were male, accelerometers were worn for an average of 76 days (95% confidence limits 73,78) over 3 months. Adjusted analyses showed a weak association between days of wear and improvement in 6-MWD, with every 30 additional days associated with an 11-meter improvement (P=.08). Our k-means clustering framework identified adherence phenotypes at two resolutions: low resolution (k=2 clusters) and high resolution (k=8 clusters). The consistently high adherence cluster trended toward a 24.6-meter improvement in 6-MWD compared to the low and declining adherence clusters (n=39; 95% CI 0.7-49.9; P=.06). The 8-cluster phenotyping revealed a richer set of adherence patterns, with the consistently high adherence cluster in this analysis having a 38.5-meter (95% CI 2.2-74.7; P=.04) improvement in 6-MWD than the low adherence cluster, as well as greater average daily steps over the 3-month intervention (mean 7518, SD 3415 vs mean 4800, SD 2920 steps; P=.008).

Conclusions

A time-series AI clustering framework identified a range of behavioral phenotypes representing different degrees of adherence to accelerometer use. Regression analysis identified a weak association between the higher adherence phenotype and functional capacity improvement in older adults undergoing mHealth-CR. Our AI-derived accelerometry adherence phenotypes may offer a new approach to tailor mHealth-CR regimens to individual patients, potentially leading to better outcomes in this high-risk population.

Trial registration

ClinicalTrials.gov NCT03978130; https://clinicaltrials.gov/study/NCT03978130.

International registered report identifier (irrid)

RR2-10.2196/32163.

Sources & attribution

Adherence to Accelerometer Use in Older Adults Undergoing mHealth Cardiac Rehabilitation: Secondary Analysis of a Randomized Clinical Trial.

Barua S, Upadhyay D, Pena S, McConnell R, Varghese A, Adhikari S, LeRoy E, Schoenthaler A, Dodson JA.

Journal of medical Internet research · 2025-12-23

DOI: 10.2196/80522 ↗PubMed · 41435373 ↗Europe PMC · Recorded licence: cc by ↗

Abstract © the original authors, reproduced under the recorded open licence. Translations support reading; use the English record to check terminology and numerical results. Our methodological interpretation is separate from the authors’ conclusions.

MoveVitals editorial interpretation · educational content · no individual clinical review recorded

Sources checked 2026-11-01

Practical guides

Read in context

·Cohort study

Activity–stroke and heart attack curves differ by accelerometer processing method

Among 90,237 UK Biobank adults free of cardiovascular disease at baseline, followed until December 2022 for 1,298 strokes and 2,031 myocardial infarctions, the shape of the link between moderate-vigorous physical activity (MVPA) and each outcome depended on how the accelerometer data were processed. For stroke, hazard fell in a straight line only with the machine-learning metric; for myocardial infarction, two metrics gave a curved decline and activity counts a straight one. The abstract gives no hazard ratios, so it shows that methods disagree, not which one is right, and the findings are observational associations.

Preventive Medicine

In-depth explainersRead study →
·Validation study/review

Smartwatch data as forensic evidence: heart rate is best validated, the rest uneven

A systematic review and meta-analysis of studies on smartwatches from four major brands, framed around digital forensics, found that heart rate was both the most studied and the most accurate measure. Step count, distance, energy expenditure, activity classification and sleep were less consistently validated, and results varied by brand, protocol and reporting. The abstract gives no pooled numbers, and most studies were run in healthy people in laboratories, so it cannot say how a particular watch performs for a particular person in daily life.

Forensic Science International

In-depth explainersRead study →
·Overview of reviews

Activity trackers: about 1,800 more steps a day, but small effects on other outcomes

An umbrella review of 39 systematic reviews and meta-analyses, covering 163,992 participants, found that activity trackers were associated with more physical activity (SMD 0.3–0.6), equating to about 1,800 extra steps and 40 minutes more walking per day, and with a bodyweight reduction of about 1 kg. Effects on blood pressure, cholesterol, glycosylated haemoglobin, quality of life and pain were typically small and often non-significant. The abstract does not say what else came with the trackers in these programs or how much the reviews overlap, so the gains cannot be credited to the device alone.

The Lancet Digital Health

In-depth explainersRead study →
·Validation study/review

Seven sleep trackers: good at spotting sleep, weak on wake and sleep stages

In a sleep laboratory, 34 healthy young adults wore a subset of seven consumer sleep trackers for three nights. Against polysomnography every device detected sleep very well (sensitivity 0.93 or higher) but caught wake poorly (specificity 0.18–0.54), and five of the seven matched or beat research actigraphy (specificity 0.39). Sleep-stage estimates were inconsistent, and the participants were healthy adults aged 18 to 35 in a fixed 8-hour bed window, with each device tested in only 11 to 20 of them, so the results say little about people with sleep problems.

Sleep

In-depth explainersRead study →
Wearables & measurement →